Rhythm Biosciences is an innovative Australian, publicly listed medical diagnostics company, with a mission goes beyond testing. We're creating a comprehensive approach to understanding cancer risk, enabling earlier treatment, and ultimately saving lives.

Early detection is critical to improving patient outcomes and reducing the global burden of cancer.

ColoSTAT^®, Rhythm Bioscience’s first simple blood-based cancer test, designed for the early detection of colorectal cancer, is an alternative screening test for individuals unable to or are unwilling to use currently available screening modalities. The test is being updated to meet relevant regulatory standards.

We recently completed the acquisition of business and assets related to the Genetype business and geneType™ product portfolio which strengthens our product portfolio. 

The geneType™ product portfolio is a world-leading personalised predictive test portfolio that uses a unique combination of genomic and clinical information to predict risk of chronic disease development. Visit www.genetype.com for the full test menu.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.